Menu

WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
📰

WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

News (English) - World Health Organization·28 days ago
#HQKtqAAo
Reading 0:00
15s threshold

WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients.

The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation.

These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect.

For each of the drugs, the interim results do not provide solid evidence of increased mortality.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.